Survival Plant-Based (Survi PB)

Single Arm, Open-label, Single-center Exploratory Study to Assess the Survival of Bifidobacteria's Strains in Human Gastro-intestinal Tract of Healthy Volunteers After 14 Days of Consumption of a Mix of 4 Freeze-dried Strains.

The aim of this study is to explore the potential of a mix of 4 freeze-dried bifidobacteria strains from Danone collection to survive in human gastro-intestinal (GI) tract of healthy volunteers after 14 days of consumption.

To this aim, one study group of 20 healthy volunteers will consume freeze-dried strains- mix twice per day diluted in 1 glass of still water during 14 consecutive days.

Study Overview

• Status: Completed
• Conditions: A03 - Digestive System; B03 - Bacteria
• Intervention / Treatment: Other: Consumption of a freeze-dried strains-mix.

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Dijon, France, 21000
    • CEN experimental

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Age 18-60 years.
2. Body Mass Index (BMI) between 18.5-30.0 kg/m2.
3. Willing to consume twice per day for at least 14 days the study product diluted in 1 glass of still water.
4. Availability to comply with the protocol and timetable.
5. Having regular bowel movements (on ≥6 days/week).
6. French speaking and reading.
7. Subject willing to adhere to the specific instructions and restrictions for the entire duration of the study.
8. Signed (written) informed consent from participant.
9. Subject is covered by a French health insurance.
10. Agree to be registered in the national database of subjects participating in clinical research.
11. Have a smartphone/computer compatible and connectable to internet, and subject is willing and able to complete the electronic Patient Reported Outcomes (ePRO) using it.
12. Women of childbearing potential must be using a medically approved method of contraception, or be with a surgically sterile partner or be with a partner of the same sex.

Exclusion Criteria:

1. Subject who used within 8 weeks prior to the screening visit or are planning to use during the conduct of this study one of the listed prohibited medications that might modify gastrointestinal function. Incidental use (1 or 2 pills/tablets) of non-steroidal anti-inflammatory drugs and aspirin is allowed, if required.
2. Subject following special diet at the screening visit (V1), or plan for such diet during the study.
3. Subject having any previous abdominal surgery, or plan for such surgery during the study.
4. Subject who underwent a general anesthesia in the preceding 4 weeks before the screening visit (V1).
5. Subject with any metabolic disease, hypertension, any inflammatory disease, any psychiatric disorder, or any gastrointestinal disorder, all these medical conditions should have been diagnosed by a physician.
6. Subject with any known food allergy or intolerance to any of the study product components or to any potential traces.
7. Active smoker with 7 or more cigarettes per week.
8. Subject doing high intensity physical activity in combination with following an enhanced diet within 1 month before screening or planned during the participation of the study.
9. Subject who underwent dental surgery within the last 4 weeks before the screening visit (V1) or plan dental surgery during the course of the study.
10. Pregnant woman or woman planning to become pregnant during the study or breastfeeding woman.
11. Participation in another study with investigational or marketed products potentially affecting the gut microbiota ≤ 4 weeks before the screening visit (V1) or plan for participation in any other intervention study during the study.
12. Employees and/or children/family members or relatives of employees of Danone Global Research & Innovation Center or the participating site.
13. Subject under guardianship or curatorship.
14. Excessive alcohol consumption during the past 6 months before the screening visit (V1).
15. Drug abuse, based on investigator's judgment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Assess the survival of Bifidobacteria's strains in the GI tract after consumption of strains mix; One study group of 20 healthy volunteers will consume freeze-dried strains- mix twice per day diluted in 1 glass of still water during 14 consecutive days.	Other: Consumption of a freeze-dried strains-mix.; One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Presence of alive bacteria of each of the provided specific strains of Bifidobacterium strains in feces after 14 days of study product consumption in healthy adults.	After 14 days of study product consumption
Comparison of the quantity of total and alive bacteria of each of the provided specific strains of Bifidobacterium strains in feces before and after 14 days of study product consumption in healthy adults.	After 14 days of study product consumption
Presence of alive bacteria of the provided specific strains of each of the Bifidobacterium strains in feces after 1 week of follow-up in healthy adults.	After 1 week of follow-up
Comparison of the quantity of total and alive bacteria of each of the provided specific strains of Bifidobacterium strains in feces after 1 week of follow-up in healthy adults.	After 1 week of follow-up

Secondary Outcome Measures

Outcome Measure	Time Frame
Dietary intakes collected by dietary recall (using MyFood24 software) of the previous day of the faecal samples collection for V2, V3 and V4 of healthy adult subjects.	After 1 week of follow-up

Collaborators and Investigators

• Sponsor: Danone Global Research & Innovation Center

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2025
• Primary Completion (Actual): March 14, 2025
• Study Completion (Actual): May 13, 2025

Study Registration Dates

• First Submitted: December 19, 2024
• First Submitted That Met QC Criteria: January 6, 2025
• First Posted (Actual): January 10, 2025

Study Record Updates

• Last Update Posted (Actual): June 22, 2025
• Last Update Submitted That Met QC Criteria: June 20, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: Survival; Intestinal microbiota; Bifidobacterium; Strains
• Other Study ID Numbers: 23REX0060157

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No